Payment overview · 2025
General Payments
$599.93
21 reported records · 4 companies
Healthcare provider profile · identity verified
Steven Michael Cicero, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · COLUMBIA, MO · NPI 1407211873
Verified facts
What the public records show
CMS Open Payments records show Steven Michael Cicero, D.O. received $599.93 in general payments during 2025 across 21 reported records.
E.R. Squibb & Sons, L.L.C. accounted for 34.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ingrezza, Rexulti.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 545 claims for Eliquis by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 2902 records involving 986 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Abilify Maintena by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Rexulti by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Ingrezza by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Abilify Maintena by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $207.41 | 34.6% | 8 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $183.32 | 30.6% | 8 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $158.96 | 26.5% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $50.24 | 8.4% | 3 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $599.93 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $233.56 | 11 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $207.41 | 8 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $158.96 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 98 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
545 | 48 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 2902 supporting records · 986 recipient NPIs · example record 1251759994 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
98 | 13 |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
73 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
98 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Potassium Chloride | Potassium Chloride | 902 | 142 |
| Gabapentin | Gabapentin | 885 | 119 |
| Furosemide | Furosemide | 875 | 137 |
| Atorvastatin Calcium | Atorvastatin Calcium | 816 | 123 |
| Levothyroxine Sodium | Levothyroxine Sodium | 622 | 104 |
| Trazodone Hcl | Trazodone Hcl | 598 | 102 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 579 | 129 |
| Eliquis | Apixaban | 545 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 525 | 77 |
| Sertraline Hcl | Sertraline Hcl | 510 | 83 |
| Divalproex Sodium | Divalproex Sodium | 505 | 69 |
| Amlodipine Besylate | Amlodipine Besylate | 497 | 74 |
| Pantoprazole Sodium | Pantoprazole Sodium | 489 | 81 |
| Metoprolol Tartrate | Metoprolol Tartrate | 453 | 60 |
| Lisinopril | Lisinopril | 448 | 71 |
| Metformin Hcl | Metformin Hcl | 408 | 56 |
| Tramadol Hcl | Tramadol Hcl | 361 | 91 |
| Mirtazapine | Mirtazapine | 353 | 63 |
| Buspirone Hcl | Buspirone Hcl | 340 | 56 |
| Famotidine | Famotidine | 331 | 58 |
| Benztropine Mesylate | Benztropine Mesylate | 330 | 48 |
| Levetiracetam | Levetiracetam | 327 | 30 |
| Quetiapine Fumarate | Quetiapine Fumarate | 311 | 60 |
| Losartan Potassium | Losartan Potassium | 275 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 262 | 39 |
| Donepezil Hcl | Donepezil Hcl | 256 | 42 |
| Lorazepam | Lorazepam | 244 | 81 |
| Carvedilol | Carvedilol | 226 | 52 |
| Olanzapine | Olanzapine | 226 | 35 |
| Divalproex Sodium Er | Divalproex Sodium | 215 | 22 |
| Risperidone | Risperidone | 213 | 35 |
| Jardiance | Empagliflozin | 208 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 200 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 198 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 196 | 37 |
| Gemtesa | Vibegron | 185 | 17 |
| Bumetanide | Bumetanide | 184 | 20 |
| Lamotrigine | Lamotrigine | 184 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 184 | 33 |
| Memantine Hcl | Memantine Hcl | 182 | 32 |
| Pregabalin | Pregabalin | 180 | 25 |
| Baclofen | Baclofen | 176 | 27 |
| Montelukast Sodium | Montelukast Sodium | 169 | 23 |
| Haloperidol | Haloperidol | 168 | 27 |
| Omeprazole | Omeprazole | 164 | 30 |
| Spironolactone | Spironolactone | 163 | 25 |
| Aripiprazole | Aripiprazole | 161 | 28 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 157 | 33 |
| Propranolol Hcl | Propranolol Hcl | 151 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 150 | 25 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 146 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 143 | 29 |
| Topiramate | Topiramate | 143 | 20 |
| Meloxicam | Meloxicam | 141 | 24 |
| Myrbetriq | Mirabegron | 139 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 135 | 47 |
| Invega Sustenna | Paliperidone Palmitate | 135 | 28 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 134 | 22 |
| Clozapine | Clozapine | 133 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 129 | 65 |
| Torsemide | Torsemide | 129 | 13 |
| Januvia | Sitagliptin Phosphate | 126 | 12 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 124 | 21 |
| Oxycodone Hcl | Oxycodone Hcl | 123 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 122 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 120 | 35 |
| Prazosin Hcl | Prazosin Hcl | 120 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 119 | 79 |
| Simvastatin | Simvastatin | 118 | 16 |
| Bupropion Xl | Bupropion Hcl | 112 | 17 |
| Midodrine Hcl | Midodrine Hcl | 110 | 14 |
| Prednisone | Prednisone | 109 | 36 |
| Citalopram Hbr | Citalopram Hydrobromide | 107 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 106 | 22 |
| Paroxetine Hcl | Paroxetine Hcl | 106 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 102 | 16 |
| Lactulose | Lactulose | 98 | 22 |
| Rexulti | Brexpiprazole | 98 | 13 |
| Celecoxib | Celecoxib | 94 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 94 | 13 |
| Clonidine Hcl | Clonidine Hcl | 93 | 16 |
| Haloperidol Decanoate | Haloperidol Decanoate | 90 | suppressed |
| Xarelto | Rivaroxaban | 90 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 87 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 86 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 86 | 15 |
| Allopurinol | Allopurinol | 84 | 14 |
| Clonazepam | Clonazepam | 83 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 82 | 53 |
| Glipizide | Glipizide | 78 | 11 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 76 | 21 |
| Cephalexin | Cephalexin | 74 | 43 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 73 | suppressed |
| Ibuprofen | Ibuprofen | 72 | 25 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 71 | 21 |
| Nystatin | Nystatin | 71 | 41 |
| Finasteride | Finasteride | 70 | 12 |
| Paliperidone Er | Paliperidone | 69 | 12 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 66 | 37 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 66 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 65 | suppressed |
| Sucralfate | Sucralfate | 62 | suppressed |
| Glimepiride | Glimepiride | 61 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 61 | 32 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 60 | 18 |
| Alprazolam | Alprazolam | 59 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 59 | 13 |
| Naproxen | Naproxen | 59 | 11 |
| Warfarin Sodium | Warfarin Sodium | 59 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 58 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 54 | 21 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 53 | suppressed |
| Matzim La | Diltiazem Hcl | 52 | suppressed |
| Scopolamine | Scopolamine | 52 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 51 | suppressed |
| Ezetimibe | Ezetimibe | 50 | 11 |
| Albuterol Sulfate | Albuterol Sulfate | 49 | 19 |
| Enalapril Maleate | Enalapril Maleate | 49 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 49 | suppressed |
| Lacosamide | Lacosamide | 48 | suppressed |
| Latanoprost | Latanoprost | 48 | 15 |
| Fenofibrate | Fenofibrate | 47 | suppressed |
| Novolog Flexpen | Insulin Aspart | 47 | 25 |
| Tradjenta | Linagliptin | 47 | suppressed |
| Trulicity | Dulaglutide | 47 | 11 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 46 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 45 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 20 |
| Benazepril Hcl | Benazepril Hcl | 44 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 44 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 44 | suppressed |
| Primidone | Primidone | 44 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 43 | 14 |
| Permethrin | Permethrin | 42 | 25 |
| Azithromycin | Azithromycin | 41 | 30 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 40 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 39 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 39 | 14 |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 39 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 38 | suppressed |
| Timolol Maleate | Timolol Maleate | 38 | 11 |
| Desmopressin Acetate | Desmopressin Acetate | 37 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 37 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 36 | suppressed |
| Entresto | Sacubitril/Valsartan | 36 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 36 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | 12 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 35 | suppressed |
| Linzess | Linaclotide | 35 | suppressed |
| Phenobarbital | Phenobarbital | 34 | suppressed |
| Vascepa | Icosapent Ethyl | 34 | suppressed |
| Amantadine | Amantadine Hcl | 33 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 25 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 33 | 14 |
| Humalog Kwikpen U-100 | Insulin Lispro | 32 | 14 |
| Temazepam | Temazepam | 32 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 32 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 31 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 31 | 11 |
| Movantik | Naloxegol Oxalate | 31 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 30 | suppressed |
| Cefdinir | Cefdinir | 30 | 27 |
| Haloperidol Lactate | Haloperidol Lactate | 30 | suppressed |
| Methylprednisolone | Methylprednisolone | 30 | 25 |
| Premarin | Estrogens, Conjugated | 30 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 30 | 16 |
| Levemir Flexpen | Insulin Detemir | 29 | 12 |
| Metoclopramide Hcl | Metoclopramide Hcl | 29 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 24 |
| Ingrezza | Valbenazine Tosylate | 28 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 27 | 19 |
| Ketoconazole | Ketoconazole | 27 | 15 |
| Methotrexate | Methotrexate Sodium | 27 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 26 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 26 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 25 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | 13 |
| Sulfasalazine | Sulfasalazine | 25 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | 18 |
| Pentoxifylline | Pentoxifylline | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Clonidine | Clonidine | 23 | suppressed |
| Fluphenazine Decanoate | Fluphenazine Decanoate | 23 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 23 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 23 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 23 | 13 |
| Sevelamer Carbonate | Sevelamer Carbonate | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 17 |
| Venlafaxine Hcl | Venlafaxine Hcl | 23 | suppressed |
| Xifaxan | Rifaximin | 23 | suppressed |
| Abilify Maintena | Aripiprazole | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 21 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 21 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Creon | Lipase/Protease/Amylase | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 20 | 17 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 20 | suppressed |
| Valproic Acid | Valproic Acid | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Vraylar | Cariprazine Hcl | 20 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 19 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 18 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 18 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 17 | suppressed |
| Nystop | Nystatin | 17 | suppressed |
| Restasis | Cyclosporine | 17 | suppressed |
| Travoprost | Travoprost | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Austedo | Deutetrabenazine | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 13 |
| Glycopyrrolate | Glycopyrrolate | 16 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 15 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 12 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 14 | suppressed |
| Ozempic | Semaglutide | 14 | suppressed |
| Phenytoin | Phenytoin | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Verapamil Sr | Verapamil Hcl | 14 | suppressed |
| Airsupra | Albuterol Sulfate/Budesonide | 13 | suppressed |
| Budesonide | Budesonide | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 13 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 13 | 11 |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Norethindrone | Norethindrone | 13 | suppressed |
| Novolog | Insulin Aspart | 13 | suppressed |
| Phenytek | Phenytoin Sodium Extended | 13 | suppressed |
| Risperidone Er | Risperidone Microspheres | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Sulfasalazine Dr | Sulfasalazine | 13 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 12 | 11 |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 12 | suppressed |
| Ivermectin | Ivermectin | 12 | suppressed |
| Lorazepam Intensol | Lorazepam | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 12 | suppressed |
| Theophylline | Theophylline Anhydrous | 12 | suppressed |
| Uzedy | Risperidone | 12 | suppressed |
| Aristada | Aripiprazole Lauroxil | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Zonisamide | Zonisamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $599.93 · 21 records | E.R. Squibb & Sons, L.L.C. | COBENFY, INGREZZA, REXULTI | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ingrezza play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error